Quantum Materials and Nano Axis have entered into a technology alliance in order to develop quantum dot technology-based nanomedicines for the diagnosis and treatment of various major diseases such as breast cancer, Alzheimer’s disease, Type 1 and Type 2 diabetes and depression.
Under this alliance, tetrapod quantum dots and quantum dots semiconductor nanocrystals, which are manufactured by Quantum Materials will be used as a basis for theranostic therapies, cell and tissue imaging technologies and pharmaceutical drug delivery from NanoAxis.
Quantum dot Technology will also be used to develop devices based on quantum dot biological microarray assays for measuring cancer bio-markers for the purpose of clinical applications and research and development of pharmaceutical products for treatment. Tetrapod Quantum dots that are synthesised emit more light as compared to dye chromophores and spheroid QD. They can also be easily bound to peptides, nucleic acids, ligands and antibodies due to their high surface to volume ratio. These features enable small and low concentration cell samples to be tested for the purpose of quantity analysis.
Research based on quantum dots has been stalled due to the fact that quantum dots are expensive and manufacturing them in large quantities is difficult. However, Quantum Materials can offer a steady supply of quantum dots that are customised based on various drug delivery systems from Quantum Materials. The company has recently announced the commencement of a microreactor continuous flow processing manufacturing of quantum dots in order to meet the needs of research and clinical trials.